^
Association details:
| Biomarker: | MSLN overexpression + PD-L1 overexpression |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | ATA3271 (Mesothelin-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
136 ATA3271: An armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors
Published date:
11/09/2021
Excerpt:
Anti-tumor effect of ATA3271 was assessed using a MSTO-211H-derived tumor cell line overexpressing MSLN and PDL1.... Upon MSLN engagement, ATA3271 showed proliferation, efficient tumor cell lysis in the presence of high-level cell-surface PD-L1 expression and secretion of effector cytokines....In an orthotopic mouse model of pleural mesothelioma, ATA3271 demonstrated anti-tumor efficacy without toxicities.
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.136
